

Pharmacy Department,
Hospital Canselor Tuanku Muhriz

Edition 23, Issue I

## GnRH Agonists—Alternative to Lucrin Inj.

The manufacturer of Lucrin Inj. in Malaysia, AbbVie has issued out a notice on product discontinuation due to supply disruption from its third party manufacturer (TPM), Takeda. According to Fierce Pharma Portal, Takeda is guilty of breach of contract as it failed to fulfill orders, maintain its plant in compliance with good manufacturing practices and to maintain a safety stock.

In HCTM, Lucrin Inj. is approved for endometriosis, uterine fibroid, treatment of prostate cancer in patients where surgical orchidectomy is contraindicated, and treatment of Central Precocious Puberty when prescribed by Urologists, O&G Specialists, Pediatric Endocrinologists, and Oncologists only.

In view of this shortage, these are the suggested alternatives:

	DISCONTINUED		Toladex 10.8 mg  Particular description of the state of t	Diphereline P.R. 375 mg
	Lucrin® Depot	Lucrin® Depot	Zoladex® LA	Diphereline®
	11.25mg	3.75mg	10.8mg	PR 3.75mg
	3 monthly	monthly	3 monthly	monthly
Advanced Prostate Cancer	✓	✓	✓	✓
Breast Cancer	✓	✓	✓	✓
Endometriosis	✓	✓		✓
Uterine Fibroid	✓	✓		<b>√</b>
Central Precocious Puberty		✓		<b>√</b>

Further information regarding the doses, route of administration and policy are listed in the table below:

Lucrin Depot (Leuprorelin Ace- tate) 11.25mg & 3.75mg	Zoladex LA (Goserelin Acetate) 10.8mg	Diphereline PR (Triptorelin Acetate) 3.75mg		
Intramuscular (IM) or Subcuta- neous (SC)	Subcutaneous (SC) only	Intramuscular (IM) only		
	SF: Urologists, O&G Specialists & Oncologists only. Patients pay RM100/syringe	A*: For treating Endometriosis, Leiomyoma Uteri & Precocious Puberty		
	REGISTERED INDICATIONS IN MALAYS	Α		
ADVANCED PROSTATE CANCER				
11.25mg every 3 months or	10.8mg every <b>3 months</b>	3.75mg every <b>4 weeks</b>		
3.75mg every 1 month		used alone or as concomitant and adjuvant to radiotherapy		
BREAST CANCER (ADJUVANT TREATMENT IN PREMENOPAUSAL WOMEN)				
11.25mg every 3 months 3.75mg every 1 month	10.8mg every <b>3 months</b>	3.75mg every <b>4 weeks</b> in combination with tamoxifen or an aromatase inhibitor. *Initiated at least 6-8 weeks prior tamoxifen or an aromatase inhibitor		





Lucrin Depot (Leuprorelin Ace- tate) 11.25mg & 3.75mg	Zoladex LA (Goserelin Acetate) 10.8mg	Diphereline PR (Triptorelin Acetate) 3.75mg			
Intramuscular (IM) or Subcuta- neous (SC)	Subcutaneous (SC) only	Intramuscular (IM) only			
REGISTERED INDICATIONS IN MALAYSIA					
ENDOMETRIOSIS					
11.25mg every 3 months or	Not registered in Malaysia for this	3.75mg every <b>4 weeks</b>			
3.75mg every 1 month	indication	Initiated within first 5 days of menstrual cycle.			
		Duration for at least 4 months and not longer than 6 months			
UTERINE FIBROID PRIOR TO SURGE	RY (ASSOCIATED WITH ANEMIA ≤8 g/dl	.)			
11.25mg every 3 months	Not registered in Malaysia for this	3.75mg every <b>4 weeks</b> ,			
3.75mg every 1 month	indication	Initiated within first 5 days of menstrual cycle.			
		Duration restricted to 3 months			
CENTRAL PRECOCIOUS PUBERTY					
Before 8 years old in girls and 9 years old in boys	Not registered in Malaysia for this indication	Before 8 years old in girls and 10 years old in boys			
Once a month		Every 4 weeks			
Starting dose of 0.3mg/kg (min		<20kg: half the dose			
7.5mg),		20-30kg: two-thirds of the dose			
Alternatively,		>30kg: 3.75mg			
≤ 25kg: 7.5mg					
> 25 to 37.5kg: 11.25mg					
>37.5mg: 15mg					

## Storage and Stability:

Zoladex® LA: Store below 30°C. Use immediately after opening pouch Diphereline® PR: Store below 30°C. Use immediately once reconstituted

## Reference:

- 1. https://www.fiercepharma.com/pharma/takeda-guilty-breach-contract-spat-abbvie-over-supply-problems-prostate-cancer-drug-lupron
- 2. Product Insert Lucrin Depot® 11.25mg & 3.75mg, Zoladex® LA 10.8mg and Dipherelin® PR 3.75mg.

PPUKM Formulary App is now available on:









A publication of Drug Information Centre

Article by Nur Hafiza Saripin nurhafiza@ppukm.ukm.edu.my

## **Co-Editors**

Izyan Diyana Ibrahim izyandi@ppukm.ukm.edu.my
Lim Sheng Hong shlim@ppukm.ukm.edu.my

03-9145 5401/5415